The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.

    • biofaust@lemmy.world
      5·
      7 hours ago

      That’s why I specified legally. Which, being American involved, I reckon still has very little meaning. I cannot undo mistakes I made 15 years ago. Stoically, I can only worry about how I can act in the present.